Biocon Ltd. shares may rise following the USFDA's approval of its key diabetes treatment drug, Kristy, potentially enhancing insulin accessibility and affordability.

Biocon announced that its subsidiary, Biocon Biologics, has received US Food and Drug Administration (USFDA) approval for Kirsty (Insulin Aspart-xjhz) 100 units/ml, to improve glycemic control in ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Brazil's Health Ministry took delivery on Friday of the first batch of insulin produced through the Partnerships for ...